The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol.
James D MillardElizabeth A MackayLaura J BonnettGeraint R DaviesPublished in: Systematic reviews (2019)
The current use of PZA for TB is based on over 60 years of clinical trial data, but this has never been synthesised to guide rationale use in future regimens and clinical trials. Systematic review registration: International Prospective Register of Systematic Reviews (PROSPERO) CRD42019138735.
Keyphrases
- clinical trial
- systematic review
- mycobacterium tuberculosis
- meta analyses
- phase ii
- randomized controlled trial
- pulmonary tuberculosis
- open label
- double blind
- study protocol
- current status
- electronic health record
- big data
- hiv aids
- metabolic syndrome
- adipose tissue
- hepatitis c virus
- antiretroviral therapy
- data analysis